The Competence and Willingness to Consent to Research Among Patients with Heroin Dependence.

Abstract:

BACKGROUND:Substance abuse research can raise ethical concerns about the comprehension and decision-making capacities of participants with drug dependence. In this study, the competence and willingness to consent to research participation were examined among patients with heroin dependence. METHODS:Twenty patients with heroin dependence and 24 healthy controls were asked to indicate if they would consent to participate in a low- and high-risk study. The MacArthur Competence Assessment Tool-Clinical Research was used to assess their consent capacities. RESULTS:Patients with heroin dependence and healthy controls did not differ significantly in their consent capacity scores. However, the patterns that underlay their decisions to consent and decline to participate in the two fictional studies were significantly different. Specifically, patients with heroin dependence were more likely to consent to participate in both studies, irrespective of the ratio of benefits to risks. Further, patients with heroin dependence who agreed to participate in the research studies did not demonstrate poorer decision-making capacities than their nonconsenting counterparts. CONCLUSIONS:Although the decision-making capacities of patients with heroin dependence and healthy controls were similar, the patterns that underlay their decisions to consent or decline to participate in the studies differed significantly between the two groups. Future studies should identify the specific factors that account for these emergent group differences.

journal_name

Ther Innov Regul Sci

authors

Zhao L,Shi H,Ying B,Li Q

doi

10.1007/s43441-020-00127-1

subject

Has Abstract

pub_date

2020-09-01 00:00:00

pages

1106-1111

issue

5

eissn

2168-4790

issn

2168-4804

pii

10.1007/s43441-020-00127-1

journal_volume

54

pub_type

杂志文章
  • Analyzing Upward Deviation of Actual vs Predicted Drug Sales in Japan for a Reasonable Drug-Pricing Policy.

    abstract:BACKGROUND:Predictions of drug sales play an important role in setting drug prices in Japan, where drug prices are highly regulated. One of 2 primary Japanese drug-pricing methodologies-the cost calculation method- refers extensively to the prediction of drug sales in establishing drug prices. Deviations from predicted...

    journal_title:Therapeutic innovation & regulatory science

    pub_type: 杂志文章

    doi:10.1177/2168479019860123

    authors: Shibata S,Fukumoto D,Suzuki T,Ozaki K

    更新日期:2019-07-16 00:00:00

  • Alternative New Mono-scaled Quantitative Benefit-Risk Assessment of Human Papillomavirus Vaccine in Japan.

    abstract:BACKGROUND:The human papillomavirus (HPV) vaccine coverage is very low in Japan since the government suspended the active encouragement of the vaccination. We aimed to conduct a benefit-risk assessment of HPV vaccination and explore different consequent scenarios to identify potential improvements to the current Japane...

    journal_title:Therapeutic innovation & regulatory science

    pub_type: 杂志文章

    doi:10.1007/s43441-020-00189-1

    authors: Matsumoto T,Matsumaru N,Scuffham P,Neels P,Tsukamoto K

    更新日期:2021-01-01 00:00:00

  • Industry and Patient Perspectives on Child Participation in Clinical Trials: The Pediatric Assent Initiative Survey Report.

    abstract:BACKGROUND:Obtaining assent from children participating in clinical trials acknowledges autonomy and developmental ability to contribute to the consent process. This critical step in pediatric drug development remains poorly understood, with significant room for improving the clarity, efficiency, and implementation of ...

    journal_title:Therapeutic innovation & regulatory science

    pub_type: 杂志文章

    doi:10.1177/2168479017716490

    authors: Lombardi D,Squires L,Sjostedt P,Eichler I,Turner MA,Thompson C

    更新日期:2018-01-01 00:00:00

  • phactMI Benchmarking Survey on Content Development and Inquiry Management.

    abstract:BACKGROUND:Medical information (MI) departments across pharmaceutical companies respond to medical inquiries about a company's products to healthcare providers, payors, patients, and caregivers. Responses provided are constructed to be relevant, accurate, scientifically balanced and delivered in a timely manner. Benchm...

    journal_title:Therapeutic innovation & regulatory science

    pub_type: 杂志文章

    doi:10.1007/s43441-020-00137-z

    authors: Byun J,Jong JA,Gangat A,Flowers T,Gazo A,Shah I

    更新日期:2020-11-01 00:00:00

  • Interdisciplinary Safety Evaluation and Quantitative Safety Monitoring: Introduction to a Series of Papers.

    abstract::The American Statistical Association and DIA have created an interdisciplinary working group of drug safety experts from academia, industry and regulatory backgrounds to explore the future direction for safety monitoring. This introduction to the series explains the background and rationale for this special section. ...

    journal_title:Therapeutic innovation & regulatory science

    pub_type: 杂志文章

    doi:10.1177/2168479018793130

    authors: Seltzer JH,Li J,Wang W

    更新日期:2019-03-29 00:00:00

  • Principled Structured Incorporation of Clinical Knowledge Into Strategic Development Decisions.

    abstract::Efficient use of limited pharmaceutical product development resources requires integrating multiple attributes, such as efficacy, safety, pharmacology, and so on, to decide at any stage whether the development of a product should proceed aggressively or slowly or be terminated. The decision process proceeds most effec...

    journal_title:Therapeutic innovation & regulatory science

    pub_type: 杂志文章

    doi:10.1177/2168479014558273

    authors: Gould AL,Krishna R,Khan A,Saltzman J

    更新日期:2015-03-01 00:00:00

  • How is the Pharmaceutical Industry Structured to Optimize Pediatric Drug Development? Existing Pediatric Structure Models and Proposed Recommendations for Structural Enhancement.

    abstract:BACKGROUND:Pediatric regulations enacted in both Europe and the USA have disrupted the pharmaceutical industry, challenging business and drug development processes, and organizational structures. Over the last decade, with science and innovation evolving, industry has moved from a reactive to a proactive mode, investin...

    journal_title:Therapeutic innovation & regulatory science

    pub_type: 杂志文章

    doi:10.1007/s43441-020-00116-4

    authors: Severin T,Corriol-Rohou S,Bucci-Rechtweg C,An Haack K,Fuerst-Recktenwald S,Lepola P,Norjavaara E,Dehlinger-Kremer M,EFGCP Children’s Medicines Working Party.,Haertter S,Cheung SYA,IQ Pediatric Working Group.

    更新日期:2020-09-01 00:00:00

  • Regulatory Trends in Drug Development in Asia Pacific.

    abstract::The Asia Pacific (AP) region is diverse and dynamic. It comprises over 40 economies, with about 24 markets that are relatively more active in terms of promulgating and implementing regulations that impact the biopharmaceutical industry and advance drug development. Although many country- and territory-specific regulat...

    journal_title:Therapeutic innovation & regulatory science

    pub_type: 杂志文章

    doi:10.1177/2168479018791539

    authors: Han FV,Weiss K

    更新日期:2019-07-01 00:00:00

  • Bowel Preparations for Colonoscopy: A Regulatory Perspective.

    abstract::Agents indicated for cleansing of the colon as a preparation for colonoscopy (bowel preps) are among the most frequently prescribed drugs for otherwise healthy patients. Better bowel preparation has been shown to translate into higher adenoma detection rates. Therefore, safety and efficacy standards need to be high. C...

    journal_title:Therapeutic innovation & regulatory science

    pub_type: 杂志文章

    doi:10.1177/2168479015577868

    authors: Gottlieb K,Turner JR,Gillespie BS,Hussain F

    更新日期:2015-09-01 00:00:00

  • Evaluation of the Performance of the South Africa Regulatory Agency: Recommendations for Improved Patients' Access to Medicines.

    abstract:BACKGROUND:Timely access to new medicines may be addressed through strengthening of registration efficiencies and timelines by establishing and refining value-added registration processes, resources, and systems. The aims of this study were to evaluate the timelines of the milestones of the South African review process...

    journal_title:Therapeutic innovation & regulatory science

    pub_type: 杂志文章

    doi:10.1007/s43441-019-00013-5

    authors: Keyter A,Salek S,Gouws J,Banoo S,Walker S

    更新日期:2020-07-01 00:00:00

  • A Multifaceted Perspective of Pharmaceutical Innovation: A Consideration of the Regulatory Role.

    abstract:BACKGROUND:The pace of innovation, the creative engine of the pharmaceutical industry, has been variably described as stagnant, stable, or accelerating depending on the metric used for assessment or the quality of evidence. If the predominant perception holds that the speed of innovation is sluggish, pressure for chang...

    journal_title:Therapeutic innovation & regulatory science

    pub_type: 杂志文章

    doi:10.1007/s43441-020-00210-7

    authors: Robberson M,Breder CD

    更新日期:2020-08-31 00:00:00

  • Regulatory Definitions and Good Pharmacovigilance Practices in Social Media: Challenges and Recommendations.

    abstract::Social media presents new challenges to the biopharmaceutical industry for conducting pharmacovigilance activities. The authors reviewed worldwide regulatory guidance documents related to monitoring of adverse events posted on social media sites and identified gaps in current regulatory definitions for pharmacovigilan...

    journal_title:Therapeutic innovation & regulatory science

    pub_type: 杂志文章

    doi:10.1177/2168479015587362

    authors: Naik P,Umrath T,van Stekelenborg J,Ruben R,Abdul-Karim N,Boland R,Ibara M,Ekuta J,Washburn D,Stergiopoulos S

    更新日期:2015-11-01 00:00:00

  • Methods for Employing Information About Uncertainty of Ascertainment of Events in Clinical Trials.

    abstract:BACKGROUND:Uncertain ascertainment of events in clinical trials has been noted for decades. To correct possible bias, Clinical Endpoint Committees (CECs) have been employed as a critical element of trials to ensure consistent and high-quality endpoint evaluation, especially for cardiovascular endpoints. However, the ef...

    journal_title:Therapeutic innovation & regulatory science

    pub_type: 杂志文章

    doi:10.1007/s43441-020-00206-3

    authors: Chen Y,Lawrence J,Hung HMJ,Stockbridge N

    更新日期:2021-01-01 00:00:00

  • Comparative Assessment of Non-trial Access to Investigational Medical Products in the U.S. and Japan.

    abstract::The U.S. and Japan have preapproval access systems for patients who have exhausted approved treatment options. We compare the systems of both countries and discuss some ethical concerns surrounding non-trial access to investigational drugs. Notable points of comparison of the two countries' systems include cost of non...

    journal_title:Therapeutic innovation & regulatory science

    pub_type: 杂志文章

    doi:10.1007/s43441-020-00228-x

    authors: Nakada H,Folkers KM,Takashima K

    更新日期:2020-10-23 00:00:00

  • Development and Validation of a Brief Measure of Self-Management Competence: The Self-Management Self-Test (SMST).

    abstract:BACKGROUND:Self-management can be considered a way of dealing with oneself and relates to actions undertaken to create order, discipline, and control. The concept is closely linked to concepts of self-efficacy and self-regulation but can be distinguished from these. The Self-Management Self-Test (SMST) is a 5-item asse...

    journal_title:Therapeutic innovation & regulatory science

    pub_type: 杂志文章

    doi:10.1177/2168479019849879

    authors: Wehmeier PM,Fox T,Doerr JM,Schnierer N,Bender M,Nater UM

    更新日期:2019-07-14 00:00:00

  • Study Designs in Multi-arm Trials for Breast Cancer: A Systematic Literature Review of Major Journals.

    abstract:BACKGROUND:Several articles showed that statistical efficiency of multi-arm randomized clinical trials (RCTs) is much better than conventional two-arm RCTs. Multi-arm RCTs attract interest mainly when the experimental treatment regimen is not optimized or several pipelines under development exist. Breast cancer is a po...

    journal_title:Therapeutic innovation & regulatory science

    pub_type: 杂志文章

    doi:10.1007/s43441-020-00141-3

    authors: Nomura S,Miyauchi Y,Ajisawa Y,Isogaya K,Sozu T

    更新日期:2020-09-01 00:00:00

  • Exact Confidence Limits on Some New Measures of Concordance and Discordance in Binary Outcomes.

    abstract::Using a measure of agreement that does not distinguish the "positive" outcome from the "negative" outcome can be sometimes misleading in assessing resemblance. To alleviate this concern, some new indices, including the "positive" and "negative" conditional synchrony measures (CSM) (or the conditional discordant measur...

    journal_title:Therapeutic innovation & regulatory science

    pub_type: 杂志文章

    doi:10.1007/s43441-019-00074-6

    authors: Lui KJ

    更新日期:2020-03-01 00:00:00

  • Considerations and Regulatory Challenges for Innovative Medicines in Expedited Approval Programs: Breakthrough Therapy and Sakigake Designation.

    abstract:BACKGROUND:In the breakthrough therapy designation (BTD) and Sakigake designation programs, rolling submission and close communication between applicants and regulatory authorities enable the timely access of patients to innovative medicines. However, challenges in the quality development, including chemistry, manufact...

    journal_title:Therapeutic innovation & regulatory science

    pub_type: 杂志文章

    doi:10.1007/s43441-019-00019-z

    authors: Kajiwara E,Shikano M

    更新日期:2020-07-01 00:00:00

  • Assessing the Quality of Database Search Strategies Utilized by Meta-analyses That Evaluate Infectious Disease Drug Therapy.

    abstract::Meta-analyses are increasingly influencing clinical practice, but significant methodological flaws have been reported. The purpose of this study was to evaluate the quality of search strategies utilized by anti-infective meta-analyses. The Embase database was searched for meta-analyses evaluating anti-infective drug t...

    journal_title:Therapeutic innovation & regulatory science

    pub_type: 杂志文章

    doi:10.1177/2168479013516774

    authors: Marler JL,Curry KY,Suda KJ

    更新日期:2014-05-01 00:00:00

  • Community Opinions on the Collection and Use of Historical Control Data in Nonclinical Toxicity Studies.

    abstract:BACKGROUND:Access and use of historical control data was identified as a top stakeholder concern across organizations according to results of a survey of needs and challenges related to nonclinical data conducted by the FDA/PhUSE Nonclinical Working Group in 2011. There is a perception there may be additional ways to c...

    journal_title:Therapeutic innovation & regulatory science

    pub_type: 杂志文章

    doi:10.1177/2168479015600203

    authors: Mihalcik LM,Bausman M,Brown P,Everds N,Feldmann J,Henck J,Potenta D,Sims J,Zandee J

    更新日期:2016-03-01 00:00:00

  • Risk Evaluation and Mitigation Strategies With Elements to Assure Safe Use: Alignment of the Goals With the Tools to Manage Risk.

    abstract::The Food and Drug Administration Amendments Act of 2007 gave the FDA the authority to require drug sponsors to submit a risk evaluation and mitigation strategies (REMS) program for those medicines with serious risks such that failure to effectively manage these risks would tip the benefit-risk balance. As of August 8,...

    journal_title:Therapeutic innovation & regulatory science

    pub_type: 杂志文章

    doi:10.1177/2168479014527749

    authors: Cronin M,Berger S,Seligman PJ

    更新日期:2014-11-01 00:00:00

  • Advancing Drug Safety Through Prospective Pharmacovigilance.

    abstract::Much has changed in a relatively short period of time. There is a raging debate over the level of evidence expected to first introduce a treatment to patients based on smaller, more adaptive data sets. Some argue for less data followed by postapproval follow-up, others for more adaptive clinical trial designs and end-...

    journal_title:Therapeutic innovation & regulatory science

    pub_type: 社论

    doi:10.1177/2168479018766887

    authors: Pitts PJ,Le Louet H

    更新日期:2018-07-01 00:00:00

  • Implementing the Principle of the 3 Rs Through the Indian Pharmacopoeia.

    abstract::Quality and safety tests are required for regulatory approval of drugs and pharmaceuticals in the country to guarantee minimum safety standards, and most of these tests include animal usage. In the case of biological medicines, these safety and quality tests have to be performed on a batch-to-batch basis and require a...

    journal_title:Therapeutic innovation & regulatory science

    pub_type: 杂志文章

    doi:10.1177/2168479015572371

    authors: Rastogi S,Kalaivani M,Bhatia AK,Prakash J,Singh GN

    更新日期:2015-09-01 00:00:00

  • Future Perspectives for the Treatment of Diabetes: Importance of a Regulatory Framework.

    abstract:BACKGROUND:The number of diabetes patients is steadily increasing worldwide. Consequently, the social burden of diabetes is huge, requiring urgent countermeasures. We performed an intensive survey of antidiabetic drugs approved in Japan, the United States, and the European Union. METHODS:Information about approved ant...

    journal_title:Therapeutic innovation & regulatory science

    pub_type: 杂志文章

    doi:10.1177/2168479018795854

    authors: Tsukamoto K,Cnop M,Mori D,Kume S,Anazawa T,Doi M,Chikazawa K,Matsumaru N

    更新日期:2019-07-01 00:00:00

  • Legislation on the Roles of the Pharmacist and Pharmacy in the Revision of the Pharmaceutical and Medical Device Act and the Pharmacists Act in Japan.

    abstract::Japan's rapidly aging population has prompted a change in the country's pharmaceutical care framework from a drug-oriented to a patient-oriented approach. Pharmacies and pharmacists are expected to play central roles in this new patient-oriented approach by reconciling medication and managing polypharmacy, conducting ...

    journal_title:Therapeutic innovation & regulatory science

    pub_type: 杂志文章,评审

    doi:10.1007/s43441-020-00215-2

    authors: Takamura K,Tachibana K,Kihira T,Nakai K,Tsutsumi Y,Kondoh M

    更新日期:2020-09-11 00:00:00

  • A Universal Framework for the Benefit-Risk Assessment of Medicines: Is This the Way Forward?

    abstract::A universal framework for the evaluation of the benefit-risk assessment of medicines during development by pharmaceutical companies and in the regulatory review by regulatory authorities is considered of value, as it would result in the systematic structured approach to support transparency in decision making. Several...

    journal_title:Therapeutic innovation & regulatory science

    pub_type: 杂志文章

    doi:10.1177/2168479014547421

    authors: Walker S,McAuslane N,Liberti L,Leong J,Salek S

    更新日期:2015-01-01 00:00:00

  • Statistical Considerations on Clinical Efficacy Studies of Biosimilar for PMDA Submission.

    abstract::In general, similar to FDA and other health authorities, the PMDA requires clinical efficacy study(ies) to evaluate equivalence between a reference biological product and a Biosimilar product for new drug applications. Even if an identical clinical efficacy study is included in both of PMDA and FDA submissions, the co...

    journal_title:Therapeutic innovation & regulatory science

    pub_type: 杂志文章

    doi:10.1007/s43441-020-00133-3

    authors: Asami Y,Pan J,Oh M,Sato A

    更新日期:2020-09-01 00:00:00

  • Lessons Learned From Hundreds of Thorough QT Studies.

    abstract:BACKGROUND:The coherence between the relationship of QTc and drug plasma concentration (this relationship is measured through the slope) and ICH E14 findings based on hundreds of QT study reports was studied. RESULTS:Based on ICH E14 analysis, our findings indicate that if the slope was not positive, in most cases (86...

    journal_title:Therapeutic innovation & regulatory science

    pub_type: 杂志文章

    doi:10.1177/2168479014563549

    authors: Zhang J,Chen H,Tsong Y,Stockbridge N

    更新日期:2015-05-01 00:00:00

  • ADHD & Pharmacotherapy: Past, Present and Future: A Review of the Changing Landscape of Drug Therapy for Attention Deficit Hyperactivity Disorder.

    abstract::Attention deficit hyperactivity disorder (ADHD) is the most common neurobiological disorder in children, with a prevalence of ~6-7%1,2 that has remained stable for decades2. The social and economic burden associated with patients3, families, and broader systems (healthcare/educational) is substantial, with the annual ...

    journal_title:Therapeutic innovation & regulatory science

    pub_type: 杂志文章

    doi:10.1177/2168479015599811

    authors: Connolly JJ,Glessner JT,Elia J,Hakonarson H

    更新日期:2015-09-01 00:00:00

  • Strategic Shift of Statistical Review on Data Quality Assessment for New Drug Applications in China.

    abstract::Data quality is critical for clinical trials to obtain robust conclusions about drug safety and efficacy evaluation. Effective data quality evaluation has been one of the major obstacles to new drug approvals in China, which hinders innovation in drug discovery and development ultimately. To improve the data quality s...

    journal_title:Therapeutic innovation & regulatory science

    pub_type: 杂志文章

    doi:10.1177/2168479018778528

    authors: Wang J,Wang G,Li M,Han J,Zeng X,Pan J,Yang J

    更新日期:2019-03-01 00:00:00